Eniluracil

Eniluracil (5-Ethynyluracil) is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor. Eniluracil irreversibly inhibits DPD, increases the oral bioavailability of 5-fluorouracil to 100%, and facilitates the uniform absorption and toxicity of 5-fluorouracil. Eniluracil can be used in cancer research of combination with fluoropyrimidines (including 5-fluorouracil) [1][2]. Eniluracil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[59989-18-3]

Product Name Alternative

5-Ethynyluracil; GW776C85

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Biochemical Assay Reagents

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/eniluracil.html

Purity

99.93

Solubility

DMSO : 5.56 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N1)NC=C(C#C)C1=O

Molecular Formula

C6H4N2O2

Molecular Weight

136.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Schilsky RL, et al. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9 (7) :1635-49.|[2]Cao S, et al. 5-Ethynyluracil (776C85) : modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res. 1994 Mar 15;54 (6) :1507-10.